

Conference Cochairs:

Joseph A. Califano, UC San Diego, San Diego, California

Maura L. Gillison, UT MD Anderson Cancer Center, Houston, Texas

Sana D. Karam, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado

Jose P. Zevallos, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

FRIDAY, JULY 7

7:00 a.m.–4:00 p.m.
517BC Foyer

Registration

7:00 a.m.–8:00 a.m.
Room 517D

Breakfast

8:00 a.m.–8:10 a.m.
Room 517A

Welcome & Opening Remarks

Joseph A. Califano, UC San Diego, San Diego, California

8:10 a.m.–10:10 a.m.

Plenary Session 1: TME & Immunobiology [CME Eligible]

Session Chair: Ravindra Uppaluri, Dana-Farber Cancer Institute, Boston, Massachusetts

8:10 a.m.–8:20 a.m.

Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance*

Nathan E. Reticker-Flynn, Stanford University, Stanford, California

8:20 a.m.–8:25a.m.

Q&A/Discussion

8:25 a.m.–8:35 a.m.

Tumor sequestered, neoantigen specific T cells are dynamically increased in circulation following neoadjuvant immunotherapy*

Clint T. Allen, National Cancer Institute, Bethesda, Maryland

8:35 a.m.–8:40a.m.

Q&A/Discussion

8:40 a.m.–9:00 a.m.

T-cell receptor gene therapy targeting HLA-II-restricted HPV antigens

Eric Tran, Earle A. Chiles Research Institute, Portland, Oregon

9:00 a.m.–9:05 a.m.

Q&A/Discussion

9:05 a.m.–9:25 a.m.

Title to be announced

Christian S. Hinrichs, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

9:25 a.m.–9:30 a.m.

Q&A/Discussion

9:30 a.m.–9:50 a.m.

Head and neck cancer takes a nerve, cancer neuroscience: Emerging hallmark of cancer

*Short talk selected from proffered abstracts


Program in Progress as of July 6, 2023

American Association for Cancer Research[®] | American Head & Neck Society

Head and Neck Cancer Conference:

Innovating through Basic, Clinical, and Translational Research

July 7-8, 2023 | Montréal, Canada



- 9:50 a.m.-9:55 a.m. Moran Amit, UT MD Anderson Cancer Center, Houston, Texas
Discussion
- 9:55 a.m.- 10:05 a.m. **Cholinergic modulation of tumor infiltrating lymphocytes in oral squamous cell carcinoma***
Ruth A. White, Columbia University Medical Center, New York, New York
- 10:05 a.m.-10:10 a.m. Q&A/Discussion


10:10 a.m.–10:30 a.m. Break
Foyer 517A

10:30 a.m.–12:15 p.m. Plenary Session 2: Next Generation Radiotherapy [CME Eligible]
Room 517A

Session Chair: Randall J. Kimple, University of Wisconsin-Madison, Madison, Wisconsin

- 10:30 a.m.-10:40 a.m. **Is TGFbeta targetable in HNC immunotherapy? Radiation lights multiple flames**
Xiao-Jing Wang, UC Davis Comprehensive Cancer Center, Sacramento, California
- 10:40 a.m.-10:45 a.m. Q&A/Discussion
- 10:45 a.m.-11:05 a.m. **Evaluating the therapeutic potential of ATR inhibitor BAY 1895344 and radiation therapy for head and neck squamous cell carcinoma**
Yvonne M. Mowery, University of Pittsburgh, Pittsburgh, Pennsylvania
- 11:05 a.m.-11:10 a.m. Q&A/Discussion
- 11:10 a.m.-11:20 a.m. **Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: from bench to bedside***
Colette J. Shen, University of North Carolina Medical Center, Chapel Hill, North Carolina
- 11:20 a.m.-11:25 a.m. Q&A/Discussion
- 11:25 a.m.-11:45 a.m. **Nodal and systemic immune effects of radiation in HNSCC**
Sana D. Karam, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado
- 11:45 a.m.-11:50 a.m. Q&A/Discussion

*Short talk selected from proffered abstracts
Program in Progress as of July 6, 2023



11:50 a.m.-12:10 pm. **Adapting to the future of radiation therapy combinations in head and neck cancers**

Andrew B. Sharabi, UCSD Moores Cancer Center, La Jolla, California

12:10 p.m.-12:15 p.m. Q&A/Discussion

12:15 p.m.–1:45 p.m. Lunch (on own)

12:30 p.m.–1:30 p.m. Optional Panel Discussion [Not CME Eligible]

Room 517A Tips for funding: From the RFA, to grant writing, to study section

Moderator: Sana D. Karam, University of Colorado Denver-Anschutz Medical Campus, Aurora, Colorado

Panelists:

Jennifer Rubin Grandis, University of California San Francisco, San Francisco, California

Xiao-Jing Wang, UC Davis Comprehensive Cancer Center, Sacramento, California

Wendy Wang, National Cancer Institute, Bethesda, Maryland

Zhong Chen, National Institute of Dental and Craniofacial Research, Bethesda, Maryland

1:45 p.m.–3:45 p.m. Plenary Session 3: Genomics: Beyond DNA [CME Eligible]

Room 517A

Session Chair: Cherie-Ann O. Nathan, LSU Health Sciences Center – Shreveport, Shreveport, Louisiana

1:45 p.m.-2:05 p.m. **Heterogeneity in HPV+ oropharynx cancers: An opportunity for rational (de)escalation**

Sidharth V. Puram, Washington University School of Medicine in St. Louis, St. Louis, Missouri

2:05 p.m.-2:10 p.m. Q&A/Discussion

2:10 p.m.-2:20 p.m. **Cooperative HPV and YAP-mediated oncogenic reprogramming of oral progenitors into cancer stem cells at single cell resolution***

Farhoud Faraji, UC San Diego Health, La Jolla, California

2:20 p.m.-2:25 p.m. Q&A/Discussion

2:25 p.m.-2:45 p.m. **Immune escape and equilibrium in head and neck cancers**

Luc G.T. Morris, Memorial Sloan Kettering Cancer Center, New York, New York

2:45 p.m.-2:50 p.m. Q&A/Discussion

*Short talk selected from proffered abstracts


Program in Progress as of July 6, 2023

American Association for Cancer Research[®] | American Head & Neck Society

Head and Neck Cancer Conference:


Innovating through Basic, Clinical, and Translational Research

July 7-8, 2023 | Montréal, Canada




- Oncogene addition to MYB-NFIB in adenoid cystic carcinomas induced in transgenic mice* [Changed to On-demand recording]**
Vicente Escamilla-Rivera, University of Arizona, Tucson, Arizona
- 2:50 p.m.-3:10 p.m. **Characterization of hypoxic tumor microenvironment in HPV-negative HNSCC**
Christine H. Chung, H. Lee Moffitt Cancer Center, Tampa, Florida
- 3:10 p.m.-3:15 p.m. Q&A/Discussion
- 3:15 p.m.-3:25 p.m. **Personalized therapeutic mRNA nano-vaccines are effective across multiple preclinical and translational models of head and neck cancer***
Natalie L. Silver, Cleveland Clinic, Cleveland, Ohio
- 3:25 p.m.-3:30 p.m. Q&A/Discussion
- 3:30 p.m.-4:00 p.m. Break**
- 4:00 p.m.-4:40 p.m. Keynote Lecture [CME Eligible]**
Room 517A
Session Chair: Andrean L. Simons-Burnett, University of Iowa, Iowa City, Iowa
- 4:00 p.m.-4:30 p.m. **Identifying determinants of immunotherapy response by spatial functional genomics**
Brian Brown, Icahn School of Medicine at Mount Sinai, New York, New York
- 4:30 p.m.-4:40 p.m. Q&A/Discussion
- 4:40 p.m.-6:30 p.m. Poster Session/Reception**
Room 517D
- SATURDAY, JULY 8**
- 7:00 a.m.-8:00 a.m. Breakfast**
Room 517D
- 8:00 a.m.-9:45 a.m. Plenary Session 4: Imaging & Biomarkers [CME Eligible]**
Room 517A
Session Chair: Carole Fakhry, Johns Hopkins Medicine, Baltimore, Maryland
- 8:00 a.m.-8:20 a.m. **Precision surgery: Shaping the future**
Maie St John, UCLA David Geffen School of Medicine, Los Angeles, California
- 8:20 a.m.-8:25 a.m. Q&A/Discussion

*Short talk selected from proffered abstracts
Program in Progress as of July 6, 2023



- 8:25 a.m.-8:35 a.m. **Detection of minimal residual disease in post-surgical drain fluid can predict locoregional recurrence in HPV-negative head and neck cancer patients***
Jose P. Zevallos, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
- 8:35 a.m.-8:40 a.m. Q&A/Discussion
- 8:40 a.m.-9:00 a.m. **Fluorescence guided surgery: Rapidly evolving applications**
Eben Rosenthal, Vanderbilt University School of Medicine, Nashville, Tennessee
- 9:00 a.m.-9:05 a.m. Q&A/Discussion
- 9:05 a.m.-9:15 a.m. **A decade in the making: screening ctDNA detection in HPV-associated HNSCC***
Daniel L. Faden, Mass Eye and Ear, Boston, Massachusetts
- 9:15 a.m.-9:20 a.m. Q&A/Discussion
- 9:20 a.m.-9:40 a.m. **Predictive biomarkers for oropharyngeal cancer - Have we had enough?**
Hisham Mehanna, University of Birmingham, Birmingham, United Kingdom
- 9:40 a.m.-9:45 a.m. Q&A/Discussion
- 9:45 a.m.–10:00 a.m. Break**
Foyer 517A
- 10:00 a.m.–11:45 a.m. Plenary Session 5: Clinical Trials [CME Eligible]**
Room 517A
Session Chair: Nicole C. Schmitt, Emory Winship Cancer Institute, Atlanta, Georgia
- 10:00 a.m.-10:20 a.m. **Immunotherapy trials in locally advanced head and neck cancer**
Sue S. Yom, UCSF School of Medicine, San Francisco, California
- 10:20 a.m.-10:25 a.m. Q&A/Discussion
- 10:25 a.m.-10:45 a.m. **Immunotherapy for HPV-associated oropharynx cancer**
Barbara A. Burtneis, Yale School of Medicine, New Haven, Connecticut
- 10:45 a.m.-10:50 a.m. Q&A/Discussion
- 10:50 a.m.-11:10 a.m. **Checkpoint blockade in recurrent and metastatic head and neck cancer – focus on novel targets**

*Short talk selected from proffered abstracts
Program in Progress as of July 6, 2023



- 11:10 a.m.-11:15 a.m. Robert I. Haddad, Dana-Farber Cancer Institute, Boston, Massachusetts
Q&A/Discussion
- 11:15 a.m.-11:25 a.m. **Allogeneic memory-like natural killer (NK) cell therapy with IL-15 superagonist with or without ipilimumab for advanced, incurable head and neck cancer: a phase 1 trial***
Glenn J. Hanna, Dana-Farber Cancer Institute, Boston, Massachusetts
- 11:25 a.m.-11:30 a.m. Q&A/Discussion
- 11:30 a.m.-11:40 a.m. **High-dimensional spatial analysis of the tumor-microenvironment to determine metastatic disease progression and response and resistance to therapy in head and neck cancer***
Angela L. Ferguson, University of Sydney, Sydney, Australia
- 11:40 a.m.-11:45 a.m. Q&A/Discussion

11:45 a.m.-12:15 p.m. Closing Keynote Lecture [CME Eligible]

Room 517A

Session Chair: Sana D. Karam, University of Colorado Denver, Denver, Colorado

- 11:45 a.m.-12:15 p.m. **Clinical implications of translational head and neck cancer research**
Jennifer Rubin Grandis, University of California San Francisco, San Francisco, California
- 12:15 p.m.-12:25 p.m. Q&A/Discussion

12:25 p.m.-12:30 p.m. Closing Remarks

Room 517A

Jose P. Zevallos, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12:30 p.m.-1:30 p.m. Optional Post-event Panel Discussion [Not CME Eligible]

Room 517A

Clinical Trial Design

Moderator: Sue Yom, UCSF School of Medicine, San Francisco, California

Panelists:

Ezra E. W. Cohen, Temps Labs, San Diego, California
Hisham Mehanna, University of Birmingham, Birmingham, United Kingdom
Nabil Saba, Emory University, Atlanta, Georgia
Quynh-Thu Le, Stanford Cancer Institute, Stanford, California

*Short talk selected from proffered abstracts
Program in Progress as of July 6, 2023